Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...
Wedge Capital Management L L P NC decreased its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 26.0% ...
China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why ...
Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...